TR201204532T1 - Treatment using re-programmed mature adult cells. - Google Patents

Treatment using re-programmed mature adult cells.

Info

Publication number
TR201204532T1
TR201204532T1 TR2012/04532T TR201204532T TR201204532T1 TR 201204532 T1 TR201204532 T1 TR 201204532T1 TR 2012/04532 T TR2012/04532 T TR 2012/04532T TR 201204532 T TR201204532 T TR 201204532T TR 201204532 T1 TR201204532 T1 TR 201204532T1
Authority
TR
Turkey
Prior art keywords
cells
differentiated
patient
retro
trans
Prior art date
Application number
TR2012/04532T
Other languages
Turkish (tr)
Inventor
Mohamed Saleh Saeed Abuljadayel Ilham
Original Assignee
Tristeim Trading (Cyprus) Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tristeim Trading (Cyprus) Limited filed Critical Tristeim Trading (Cyprus) Limited
Publication of TR201204532T1 publication Critical patent/TR201204532T1/en

Links

Landscapes

  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Retro (geriye dönük olarak)-farklılaştırılmış, trans (dokular arası olarak)-farklılaştırılmış veya yeniden farklılaştırılmış hücreler gibi yeniden programlanmış hücreler kullanılarak bır hastadaki çeşitli hastalık, bozukluk veya durumların tedavi edilmesine ilişkin bir yöntem. Yöntem, hastadan adanmış hücrelerin elde edilmesini, adanmış hücreler retro-farklılaştırmaya tabi tutularak retro-farklılaştırılmış hedef hücrelerin elde edilmesini ve retro-farklılaştırılmış hücrelerin hastaya verilmesini içermektedir. Belirli uygulamalarda yöntem, hastadan adanmış hücrelerin elde edilmesini, adanmış hücreler trans-farklılaştırmaya tabi tutularak trans-farklılaştırılmış hedef hücrelerin elde edilmesini ve trans-farklılaştırılmış hedef hücrelerin hastaya verilmesini içermektedir. Retro-farklılaştırılmış veya trans-farklılaştırılmış hedef hücreler hastadaki doku veya hücreleri onarmakta veya yenilemektedir.A method of treating a variety of diseases, disorders, or conditions in a patient using reprogrammed cells, such as retro (retrospectively) -differentiated, trans-tissue-differentiated, or differentiated cells. The method comprises obtaining dedicated cells from the patient, subjecting the dedicated cells to retro-differentiation to obtain retro-differentiated target cells and delivering the retro-differentiated cells to the patient. In certain embodiments, the method comprises obtaining dedicated cells from the patient, subjecting the dedicated cells to trans-differentiation to obtain trans-differentiated target cells, and delivering the trans-differentiated target cells to the patient. Retro-differentiated or trans-differentiated target cells repair or regenerate tissues or cells in the patient.

TR2012/04532T 2009-10-19 2009-10-19 Treatment using re-programmed mature adult cells. TR201204532T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TR201204532 2009-10-19

Publications (1)

Publication Number Publication Date
TR201204532T1 true TR201204532T1 (en) 2012-09-21

Family

ID=47005062

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2012/04532T TR201204532T1 (en) 2009-10-19 2009-10-19 Treatment using re-programmed mature adult cells.

Country Status (1)

Country Link
TR (1) TR201204532T1 (en)

Similar Documents

Publication Publication Date Title
TN2012000157A1 (en) Treatment using reprogrammed mature adult cells
TR201911199T4 (en) Treatment to increase cell growth.
MX2022004300A (en) Composition and method for diagnosis and treatment of diseases associated with neurite degeneration.
WO2009111375A3 (en) Treatment, diagnostic, and method for discovering antagonist using sparc specific mirnas
MY176820A (en) Egfr and c-met fibronectin type iii domain binding molecules
IN2015DN02938A (en)
MX342200B (en) Method for processing mesenchymal stem cells and the use thereof in the treatment of diseases associated with oxidative stress.
MX2019006379A (en) Small molecule trail gene induction by normal and tumor cells as an anticancer therapy.
WO2009089110A3 (en) Methods for repair and regeneration of bone marrow
EA201101568A1 (en) TREATMENT OF EX VIVO IMMUNOLOGICAL DISORDERS THROUGH PKC-TETA INHIBITORS
MX2020011415A (en) Methods of using zscan4 for rejuvenating human cells.
BR112013004700A2 (en) method for preventing or treating cardiovascular disease or disorder
MX362098B (en) Treatment of peripheral vascular disease using umbilical cord tissue-derived cells.
WO2010097788A3 (en) Visfatin therapeutic agents for the treatment of acne and other conditions
NZ616048A (en) Administration of iloprost as aerosol bolus
EP2400971A4 (en) Treatment of immunosuppression-related disorders
MX2013015347A (en) Egfr targeted therapy.
MX354667B (en) Methods for treating a stroke-related sensorimotor impairment using aminopyridines.
MX2012002456A (en) Novel forms of a multicyclic compound.
TR201204532T1 (en) Treatment using re-programmed mature adult cells.
WO2012068341A3 (en) Wnt1 for treatment of cardiovascular disorders and injuries
CL2015003505A1 (en) Mesenchymal stem cells derived from chorion and conditioned medium as an inducer of angiogenesis application in the treatment of cardiac degeneration
WO2014005153A3 (en) Methods for treating mds1-evi1 mediated cancer
ATE542547T1 (en) USE OF ADIATIVE TISSUE CELL FRACTIONS FOR TISSUE REGENERATION AFTER RADIATION
WO2012177565A3 (en) Regulation of macrophage activation using mir - 125b